Xencor is trading 27.64% higher at $32.14 after updated Phase 1 XmAb819 results in advanced clear cell renal cell carcinoma. - At 400 mcg/kg, 5 of 11 evaluable patients had confirmed responses (45.5%); the six-month progression-free survival estimate was 82%. - Xencor outlined plans for potential registration-enabling development by the end of 2027. - Results were presented at ESMO on October 25 and discussed in an October 26 webcast. MarketWatch and Investors.com also reported gains after the trial data, supporting the data as the catalyst.